Cécile Tharaud appointed as President and Managing Partner of Inserm Transfert Initiative
The Supervisory Board of Inserm Transfert Initiative – which is composed of Bpifrance1 , Inserm Transfert, AbbVie, Boehringer Ingelheim Venture Fund, MSD, GlaxoSmithKline, Ipsen, Pfizer, MSD (Merck & Co) and Shire – has appointed Cécile Tharaud as President and Managing Partner of Inserm Transfert Initiative.
Cécile Tharaud was hitherto the CEO of Inserm Transfert.
Inserm Transfert Initiative was established in 2005 and is dedicated to the pre-seed and seed financing of young innovative start-ups in health and life sciences. In early 2012, Inserm Transfert Initiative finalised its second round of fund-raising, gathering a total €35.5m and increasing the company’s equity capital to €39.7m. As of today, its portfolio encompasses 18 high-innovativepotential companies.